Videos

Leffler describes progress made in the understanding of celiac disease but points to continued challenges in diagnosis and management.

This episode of the SOCS podcast features an in-depth discussion between Tiffany Mayo, MD, Steven Daveluy, MD, and patient advocate Jasmine Ivanna Espy.

Jeemin Kwon, MD, describes the role GI symptom-related anxiety plays in shaping dietary patterns and altering the gut microbiome in patients with IBS.

An analysis of several datasets cataloguing the switch revealed that dosing can be extended up to 2 weeks for patients with nAMD who received prior anti-VEGF therapy.

The recent trial indicates that the oral treatment gildeuretinol reduces GA lesion growth rates, as well as achieving better BCVA scores.

A pair of experts discuss their research on trends in the use of GLP-1 RAs in patients with IBD as well as their safety and efficacy in this patient population.

Findings suggest sleep disorders are common in PBC and are linked to worse biochemical markers, greater symptom burden, and reduced treatment response rates.

Najy Issa, MD, describes “underwhelming” universal HBV screening uptake since 2023 CDC guidelines were implemented and steps to get more patients screened.

Horst explains the importance of addressing depression and anxiety in patients with IBD and steps clinicians can take to support their patients’ mental health.

In this episode, hosts explore updates on continuous glucose monitoring (CGM) systems from April 2025.

EBX-102-02 was well tolerated and led to clinically meaningful improvements across multiple symptom domains in patients with IBS-C.

Gregory Cote, MD, reviews SHARP trial data suggesting ERCP with miES does not reduce acute pancreatitis risk in acute recurrent pancreatitis and pancreas divisum.

A post hoc analysis of data from the PULSAR trial indicates that patients with aflibercept 8 mg achieved disease activity control early and in high proportion.

Anthony Kerbage, MD, explains the heightened risk of repeat screening colonoscopy among patients with a primary language other than English.

Mazen Noureddin, MD, MHSc, reviews findings from a phase 2 study of efimosfermin alfa (BOS-580) for F2/F3 fibrosis due to MASH.

Findings from a posthoc analysis of 2 phase 3 trials suggest seladelpar monotherapy has similar safety and efficacy to seladelpar combined with UDCA.

Fendrick describes patients’ desire for green screening options and reviews findings from a study comparing the environmental impact of screening tools.

Panelists discuss how understanding the causes of iron deficiency anemia, selecting appropriate treatments such as intravenous iron, and tailoring therapies to individual patient needs are critical for effective management, particularly in patients with gastrointestinal conditions.

Zhang describes the importance of multidisciplinary care for preventing alcohol relapse post-transplant, citing success from Mass General’s LIFT Clinic.

Gold explains misconceptions about who is affected by EoE and describes the importance of understanding the impact of SDoH in this patient population.

Fendrick describes the importance of follow-up colonoscopy after a positive result on a noninvasive test and factors influencing follow-up rates.

Pontecorvi describes the unique features of the EndoZip system and reviews findings from a study on its use for treating obesity-related comorbidities.

Feuerstadt explains recent advances in treating recurrent C diff and reviews new data on the safety and administration of fecal microbiota, live-jslm (Rebyota).

HCPLive spoke with Hoyt about the new Early Childhood Anaphylaxis Collaborative, which strives to educate early childcare centers on how to recognize and respond to anaphylaxis.

Shah explores the impact of hyperosmolarity on tear film post-cataract surgery, emphasizing the need for enhanced dry eye management strategies.

A new study highlights rapid relief and high satisfaction with PFHO for dry eye disease, showing significant symptom improvement within minutes.

Liver Lineup: Updates & Unfiltered Insights is a hepatology podcast from HCPLive hosted by Nancy Reau, MD, and Kimberly Brown, MD, exploring the latest news and research in liver disease.

In this episode, hosts explore the promise of semaglutide 2.4 mg in improving liver outcomes for MASH in the Phase 3 ESSENCE trial.